In vitro and in silico evaluation of NF-κB targeted costunolide action on estrogen receptor-negative breast cancer cells-A comparison with normal breast cells

Phytotherapy Research

Volumn 28, Issue 10, 2014, Pages 1499-1505

  Pitchai, Daisy ^a   Roy, Anita ^a   Banu, Sakhila ^b  

^a HOLY CROSS COLLEGE   (India)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

anticancer; breast cancer; docking; Nf B subunits; phytotherapy

Indexed keywords

COSTUNOLIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; PROTEIN P52; SYNAPTOTAGMIN I; ESTROGEN RECEPTOR; SESQUITERPENE;

ARTICLE; BINDING AFFINITY; BREAST CANCER CELL LINE; BREAST CELL; CELL VIABILITY; CHEILOCOSTUS SPECIOSUS; COMPARATIVE EFFECTIVENESS; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR DOCKING; PROTEIN EXPRESSION; RHIZOME; WESTERN BLOTTING; BREAST; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; COSTUS; CYTOLOGY; DRUG EFFECTS; FEMALE; METABOLISM; TUMOR CELL LINE;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COSTUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MOLECULAR DOCKING SIMULATION; NF-KAPPA B; RECEPTORS, ESTROGEN; SESQUITERPENES;

EID: 84908505670     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5155     Document Type: Article

References (31)

1. Baldwin AS,. 2001. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Invest 107: 241 - 246.
2. Biswas DK, Martin KJ, McAlister C, et al. 2003. Cancer Res 63: 290 - 295.
3. Choi YK, Seo HS, Choi HS, Kim SR, Shin YC, Ko SG,. 2011. Induction of Fas-mediated extrinsic apoptosis, p21WAF1-related G2/ M cell cycle arrest and ROS generation by costunolide in estrogen receptor-negative breast cancer cells, MDA-MB-231. Mol Cell Biochem 363: 119 - 128.
4. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS,. 2000. Selective activation of NF-κ B subunits in human breast cancer: potential roles for NF-κ B2/p52 and for Bcl3. Oncogene 19: 1123 - 1131.
5. Cragg GM, Kingston DGI, Newman DJ,. 2005. Anticancer Agents from Natural Products. Brunner-Routledge Psychology Press: Taylor & Francis Group, Boca Raton, FL.
6. Daisy P, Lizzy Jaculine A, Rajalakshmi M,. (2012a). Identification of dual agonistic novel ligands for insulin receptor and PPARγ through molecular docking. Int J Pharm Pharm Sci 4: 142 - 147.
7. Daisy P, Suveena S, Sr., Lilly V,. 2011. Molecular docking of medicinal compound Lupeol with autolysin and potential drug target of UTI. J Chem Pharm Res 3 (3): 557 - 562.
8. Daisy P, Vijayalakshmi P, Selvaraj C, Singh SK, Saipriya K,. 2012b. Targeting Multidrug Resistant Mycobacterium tuberculosis HtrA2 with Identical Chemical Entities of Fluoroquinolones. Indian J Pharm Sci 74 (3): 217 - 222.
9. Dechant KL, Brogden RN, Pilkington T, Faulds D,. 1991. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42 (3): 428 - 467.
10. Duraipandiyan V, Naif Abdullah Al-Harbi, Ignacimuthu S, Muthukumar C,. 2012. Antimicrobial activity of sesquiterpene lactones isolated from traditional medicinal plant, Costus speciosus (Koen ex.Retz.) Sm. BMC Complement Altern Med 12: 13.
11. Eliza J, Daisy P, Ignacimuthu S,. 2010. Antioxidant activity of costunolide and eremanthin isolated from Costus speciosus(Koen ex. Retz) Sm. Chem Biol Interact 88 (3): 467 - 472.
12. Eliza J, Daisy P, Ignacimuthu S, Duraipandiyan V,. 2009. Normo-glycemic and hypolipidemic effect of costunolide isolated from Costus speciosus (Koen ex. Retz.)Sm. in streptozotocin-induced diabetic rats Chem Biol Interact 179 (2-3): 329 - 334.
13. Ghosh S, Karin M,. 2002. Missing pieces in the NF-κ B puzzle. Cell 109: S81 - S96.
14. Hanahan D, Weinberg RA,. 2000. The Hallmarks of cancer. Cell 100: 57 - 70.
15. Harikrishna N, Goulet RJ,. 2002. NF-kB and Breast Cancer. Curr. Probl. Cancer.
16. Jeong SJ, Itokawa T, Shibuya M, et al. 2002. Costunolide, a sesquiterpene lactone from Saussurea lappa, inhibits the VEGFR KDR/Flk-1 signaling pathway. Cancer Lett 187: 129 - 133.
17. Karin M, Neriah YB,. 2000. Phosphorylation Meets Ubiquitination: The Control of NF-κ B Activity. Annu Rev Immunol 18: 621 - 663.
18. Kim HJ, Hawke N, Baldwin AS,. 2006. NF-κ B and IKK as therapeutic targets in cancer. Cell Death Differ 13: 738 - 747.
19. Kim JH, Yang YI, Lee KT, Park HJ, Choi JH,. 2011. Costunolide induces apoptosis in human endometriotic cells through inhibition of the prosurvival Akt and nuclear factor kappa B signaling pathway. Biol Pharm Bull 34 (4): 580 - 585.
20. Li Q, Verma IM,. 2002. NF-κ B regulation in the immune system. Nat Rev Immunol 2: 725 - 734.
21. Madrid LV, Mayo MW, Reuther JY, Baldwin AS,. 2001. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276 (22): 18934 - 18940.
22. McConkey BJ, Sobolev V, Edelman M,. 2002. The performance of current methods in ligand-protein docking. Curr Sci 83: 845 - 855.
23. Nam NH,. 2006. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6: 945 - 951.
24. Rasul A, Parveen S, T Ma,. 2012. Costunolide: A novel anti-cancer sesquiterpene lactone. Bangladesh J Pharmacol 7: 6 - 13.
25. Rayan NA, Baby N, Pitchai D, et al. 2011. Costunolide inhibits proinflammatory cytokines and iNOS in activated murine BV2 microglia. Front Biosci 3: 1079 - 1091.
26. Selvakumar E, Hsieh TC, Joseph MWU,. 2008. Growth Inhibition of Human MDA-MB-231 Breast Cancer Cells by δ-Tocotrienol Is Associated with Loss of Cyclin D1/CDK4 Expression and Accompanying Changes in the State of Phosphorylation of the Retinoblastoma Tumor Suppressor Gene Product. Anticancer Res 28: 2641 - 2648.
27. Siebenlist U, Franzoso G, Brown K,. 1994. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10: 405 - 455.
28. Srivastava SK, Abraham A, Bhat B, et al. 2006. Synthesis of 13-amino costunolide derivatives as anticancer agents. Bioorg Med Chem Lett 16: 4195 - 4199.
29. Yamamoto Y, Gaynor RB,. 2001. Therapeutic potential of inhibition of the NF-κ B pathway in the treatment of inflammation and cancer. J Clin Invest 107 (2): 135 - 142.
30. Zhang S, Won YK, Ong CN, Shen HM,. 2005. Anti-cancer potential of sesquiterpene lactones: Bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 5: 239 - 249.
31. Zhu F, Qin C, Tao L, et al. 2011. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci 108: 12943 - 12948.